Treatment of Multiple Sclerosis with Cladribine Tablets: Literature Review and the Guidance of the Lithuanian Association of Neurologists
Cladribine is a disease-modifying drug used for the treatment of the highly active relapsing-remitting form of multiple sclerosis. Cladribine is a purine nucleoside analogue which selectively targets lymphocyte subpopulations involved in the pathogenesis of multiple sclerosis, and therefore it is c...
Saved in:
Main Authors: | R. Kizlaitienė, D. Mickevičienė, L. Malcienė, N. Giedraitienė, R. Balnytė, D. Jatužis |
---|---|
Format: | Article |
Language: | English |
Published: |
Vilnius University Press
2024-03-01
|
Series: | Neurologijos seminarai |
Subjects: | |
Online Access: | https://www.journals.vu.lt/neurologijos_seminarai/article/view/34912 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
by: Heinz Wiendl, et al.
Published: (2025-02-01) -
From pathogenesis to new developments in treatment of primary progressive multiple sclerosis. Literature review
by: A. Juknelytė, et al.
Published: (2020-03-01) -
Optic neuritis and multiple sclerosis association
by: L. Matukynaitė, et al.
Published: (2020-09-01) -
Recommendations for the treatment of multiple sclerosis with disease-modifying drugs during the COVID-19 pandemic
by: R. Kizlaitienė, et al.
Published: (2020-06-01) -
Willingness and Hesitancy to Vaccinate Against COVID-19 in People with Multiple Sclerosis
by: D. Bučaitė, et al.
Published: (2023-11-01)